OPTIMIZERx Corporation

October 14, 2014 07:05 ET

Merriman Capital Research Reiterates Buy, $3.00 Target on OptimizeRx Corporation (OPRx)

ROCHESTER, MI--(Marketwired - October 14, 2014) - San Francisco-based Merriman Capital's updated its coverage on OptimizeRx Corporation (OTCQB: OPRX) based on their work at the CBInet EHR Pharmaceutical conference and reiterated a buy rating and stock target price of $3.00.

The report highlights the Company's expanding distribution capacity, its value proposition, strong leadership position in the growing e-coupon market, industry trends, operating leverage, and its strong, debt-free, balance sheet.

"Our discussions with conference attendees, OPRX executives and senior field personnel, as well as key OPRX channel partners bolster our conviction in the company's long-term Outlook," stated the Merriman Capital research report. "We were encouraged by the broad-based industry endorsements we encountered for e-couponing in general and OPRX in particular. We found multi-channel marketing managers from blue-chip Pharmaceutical companies as well as representatives from leading EHR software vendors that actively evangelized and testified to the virtues and high ROI of OPRX's solutions. Overall, we came away very comfortable with OPRX's strong competitive position in the e-couponing niche, the company's ability to continue to grow its EHR distribution reach, the healthcare industry's secular e-prescribing adoption trends, and OPRX's long-term growth opportunity."

Click Here for Full Report or go to

About OptimizeRx Corp
OPTIMIZERx Corp. (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies more effective ways to expand patient awareness, access and adherence to their medications. For more information, please go to or

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:
    OptimizeRx Corporation
    Doug Baker
    Email contact
    248-651-6568 x807